Motif Bio to Present at the 7th Annual Trout Group Hamptons CEO Roundtable Conference on August 17th
August 14 2017 - 8:30AM
Motif Bio plc (AIM:MTFB) (NASDAQ:MTFB) ("Motif" or the "Company"),
the clinical stage biopharmaceutical company specializing in
developing novel antibiotics, announced today that CEO Graham
Lumsden will present an overview of the company and near-term value
drivers for its flagship product, Iclaprim, which is in late Phase
3 clinical trials as part of The Catalyst Hour at the 7th Annual
Trout Group Hamptons CEO Roundtable Conference. The conference will
take place on August 17th, 2017 in Bridgehampton, New York.
For further information please contact:
Motif Bio plc |
info@motifbio.com |
Graham Lumsden (Chief Executive Officer) |
|
Robert
Dickey IV (Chief Financial Officer) |
|
|
|
Peel Hunt LLP (NOMAD & BROKER) |
+ 44 (0)20 7418 8900 |
Dr
Christopher Golden |
|
Oliver
Jackson |
|
|
|
Northland Capital Partners Limited
(BROKER) |
+44
(0)203 861 6625 |
Patrick Claridge/ David Hignell |
|
John
Howes/ Rob Rees (Broking) |
|
|
|
Walbrook PR Ltd. (FINANCIAL PR & IR) |
+44 (0) 20 7933 8780
or motifbio@walbrookpr.com |
Paul
McManus |
Mob: +44 (0)7980 541 893 |
Mike
Wort |
Mob: +44 (0)7900 608 002 |
|
|
MC Services AG (EUROPEAN IR) |
+49 (0)89 210 2280 |
Raimund
Gabriel |
|
|
|
The Trout Group (US IR) |
+1 (646 )378-2938 |
Michael
Gibralter |
mgibralter@troutgroup.com |
Notes to Editors
About Iclaprim
Iclaprim is a novel antibiotic that has a
different and underutilised mechanism of action compared to other
antibiotics. Iclaprim exhibits potent activity against
Gram-positive clinical isolates of many genera of staphylococci,
including methicillin resistant Staphylococcus
aureus (MRSA). Iclaprim is rapidly bactericidal, achieving
99.9% in-vitro kill against MRSA within 4 to 6 hours of drug
exposure versus 8 to 10 hours for vancomycin. To date, iclaprim has
been studied in over 1,300 patients and healthy volunteers.
Iclaprim is administered intravenously at a fixed dose with no
dosage adjustment required in patients with renal impairment, or in
obese patients. The iclaprim fixed dose may help reduce the
resources required in hospitals since dosage adjustment by health
care professionals is avoided and overall hospital treatment costs
may be lower, especially in renally impaired patients.
About Motif Bio
Motif Bio plc (AIM:MTFB) is a clinical-stage
biopharmaceutical company, engaged in the research and development
of novel antibiotics designed to be effective against serious and
life-threatening infections in hospitalised patients caused by
multi-drug resistant bacteria, including MRSA
(methicillin-resistant Staphylococcus aureus). The Company’s lead
product candidate, iclaprim, is being developed for high risk MRSA
patient populations. The first proposed indication, and near-term
commercial opportunity, is for the treatment of acute bacterial
skin and skin structure infections (ABSSSI), one of the most common
bacterial infections, with 3.6 million patients hospitalised
annually in the U. S. The Company believes that iclaprim is
suitable for first-line empiric therapy in ABSSSI patients,
especially those with renal impairment, with or without diabetes,
due to its underutilised mechanism of action, targeted spectrum of
activity, low propensity for resistance development, fixed dose
administration, clearance of inactive metabolites through the
kidneys and favourable tolerability profile. The Company also plans
to develop iclaprim for hospital acquired bacterial pneumonia
(HABP), including ventilator associated bacterial pneumonia (VABP),
as there is a high unmet need for new therapies in this indication
and iclaprim has demonstrated initial evidence of efficacy in a
Phase 2 trial in patients with HABP. Additionally, in a clinical
study evaluating the tissue distribution of an IV dose of Iclaprim
in relevant lung compartments, high concentrations were found in
epithelial lining fluid and alveolar macrophages, achieving levels
up to 20- and 40-fold higher, respectively, than in plasma.
Iclaprim has been studied in an animal model of chronic pulmonary
MRSA infection which mimics the pathophysiology observed in
patients with cystic fibrosis. Data will be presented at ID Week in
October 2017. Iclaprim has received Qualified Infectious Disease
Product (QIDP) designation from the FDA together with Fast Track
status. Upon acceptance of the NDA, iclaprim will receive Priority
Review status and, if approved as a New Chemical Entity, will be
eligible for 10 years of market exclusivity in the U.S. from the
date of first approval, under the Generating Antibiotic Incentives
Now Act (the GAIN Act). In Europe, 10 years of data exclusivity is
anticipated.
Forward-Looking Statements
This press release contains forward-looking
statements. Words such as “expect,” “believe,” “intend,” “plan,”
“continue,” “may,” “will,” “anticipate,” and similar expressions
are intended to identify forward-looking statements.
Forward-looking statements involve known and unknown risks,
uncertainties and other important factors that may cause Motif
Bio’s actual results, performance or achievements to be materially
different from any future results, performance or achievements
expressed or implied by the forward-looking statements. Motif Bio
believes that these factors include, but are not limited to, (i)
the timing, progress and the results of clinical trials for Motif
Bio’s product candidates, (ii) the timing, scope or likelihood of
regulatory filings and approvals for Motif Bio’s product
candidates, (iii) Motif Bio’s ability to successfully commercialise
its product candidates, (iv) Motif Bio’s ability to effectively
market any product candidates that receive regulatory approval, (v)
Motif Bio’s commercialisation, marketing and manufacturing
capabilities and strategy, (vi) Motif Bio’s expectation regarding
the safety and efficacy of its product candidates, (vii) the
potential clinical utility and benefits of Motif Bio’s product
candidates, (viii) Motif Bio’s ability to advance its product
candidates through various stages of development, especially
through pivotal safety and efficacy trials, (ix) Motif Bio’s
estimates regarding the potential market opportunity for its
product candidates, and (x) the factors discussed in the section
entitled “Risk Factors” in Motif Bio plc’s Annual Report on Form
20-F filed with the SEC on May 1, 2017, which is available on the
SEC’s web site, www.sec.gov. Motif Bio plc undertakes no obligation
to update or revise any forward-looking statements.
Motif Bio (LSE:MTFB)
Historical Stock Chart
From Mar 2024 to Apr 2024
Motif Bio (LSE:MTFB)
Historical Stock Chart
From Apr 2023 to Apr 2024